We are international
Donate
TEXT SIZE   
    back

The 52nd Annual Meeting of the American Society of Hematology took place in Orlando, Florida December 4-7, 2010. The webcasts taped at the meeting are reports on the current status of some of the most interesting research in myeloma. Please be aware that at the time of posting, in some cases, the interviewees are reporting on interim data from incomplete clinical trials. Therefore not all the data presented are final results, and it is possible that results will be different when the data has matured with long-term follow-up. None of this research has yet been peer-reviewed and published in a medical journal.

Velcade
Others
Dr. Cavo - Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
Michele Cavo, MD
Bologna University School of Medicine
Bologna Italy
Dr. Cavo - Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study
Michele Cavo, MD
Bologna University School of Medicine
Bologna Italy

Dr. Palumbo - Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors
Antonio Palumbo, MD
University of Torino
Torino, Italy
Dr. Kumar - Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota
USA

Dr. Bladé - A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Joan Bladé, MD
Hospital Clinic
Barcelona, Spain
Dr. Jakubowiak - Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial
Andrzej J Jakubowiak, MD, PhD
University of Michigan
Ann Arbor, Michigan
USA

Dr. Dimopoulos - Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study
Meletios A. Dimopoulos, MD
Greek Myeloma Study Group
Greece
Dr. Ghobrial - Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Ghobrial - Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
USA
Dr. Richardson - Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
USA

Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Philippe Moreau, MD
University Hospital
Nantes, France
Dr. Kaufman - Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study
Jonathan L. Kaufman
Winship Cancer Institute of Emory University
Atlanta, Georgia
USA

Dr. Niesvizky - A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York
USA
Dr. Niesvizky - Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York
USA